Medgenics (MDGN) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Medgenics Reports Fourth Quarter and Full Year 2015 Results and Advancement of NFC-1 Development Programs
February 17, 2016 8:00 AM ESTPHILADELPHIA, PA -- (Marketwired) -- 02/17/16 -- Medgenics, Inc. (NYSE MKT: MDGN)
Enrollment Initiated in Groundbreaking Non-interventional Phenotype/Genotype Study of mGluR Mutations in ADHD IND Clearance Received for 22Q11.2 Deletion SyndromeMedgenics, Inc. (NYSE MKT: MDGN) today reported financial results for the three and twelve months ended December 31, 2015, as well as several key business and clinical development program highlights.
"We have made tremendous progress over the past year in transitioning our strategy toward becoming a leading genomic... More
